SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
JANUARY 9, 2006
Date of Report (Date of earliest event reported)
|
Haemonetics Corporation |
|
(Exact Name of Registrant as Specified in its Charter) |
|
|
|
Massachusetts |
|
(State or Other Jurisdiction of Incorporation) |
|
1-10730 |
|
04-2882273 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
400 Wood Road Braintree, MA |
|
02184 |
|
|
|
|
|
(Address of Principal Executive Office) |
|
(Zip Code) |
|
781-848-7100 |
|
(Registrant’s Telephone Number, Including Area Code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
o |
Soliciting material pursuant to Rule 14a12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
|
|
|
|
Item 5.02 Departure of Principle Officer
Ronald J. Ryan, Vice President and Chief Financial Officer, is retiring from Haemonetics Corporation. Mr. Ryan will continue to serve as Chief Financial Officer until a successor is appointed. He will also remain with the Company for a period of time following the appointment of a new Chief Financial Officer to assist in the transition and to lead Haemonetics’ global Enterprise Resource Planning (“ERP”) initiative. Mr. Ryan will remain a member of the Company’s Operating Committee until his retirement.
Item 9.01 Financial Statements and Exhibits.
|
(d) |
Exhibits. |
|
|
|
|
|
|
EXHIBIT 99.1 |
|
Press Release of Haemonetics Corporation dated January 9, 2006 announcing the retirement of Ronald J. Ryan, Vice President and Chief Financial Officer. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Haemonetics Corporation |
|
|
|
|
|
|
|
|
|
|
Date: January 9, 2006 |
By: |
/s/ Ronald J. Ryan |
|
|
|
|
|
|
|
Ronald J. Ryan, |
|
|
|
Vice President and Chief Financial Officer |
EXHIBIT INDEX
|
EXHIBIT 99.1 |
|
Press Release of Haemonetics Corporation dated January 9, 2006 announcing the retirement of Ronald J. Ryan from the position of Chief Financial Officer. |
Exhibit 99.1
99.1 Press Release issued by Haemonetics Corporation on January 9, 2006.
|
FOR RELEASE: |
|
CONTACT: |
|
Date: January 10, 2006 |
|
Julie Fallon |
|
Time: 4:15 PM Eastern |
|
Tel. (781) 356-9517 |
|
|
|
Alternate Tel. (617) 320-2401 |
|
|
|
fallon@haemonetics.com |
HAEMONETICS ANNOUNCES CFO RETIREMENT
BRAINTREE, MA, January 9, 2006 – Haemonetics Corporation announced today that Ronald Ryan will retire after nearly eight years as Chief Financial Officer. Mr. Ryan will continue to serve as CFO until a successor is appointed. The firm of Heidrich & Struggles has been retained to lead the search for a new CFO.
Brad Nutter, Haemonetics’ CEO, said, “I credit Ron’s disciplined leadership for the consistent improvements in Haemonetics’ cash flow, profitability and balance sheet. I am pleased that Ron has agreed to remain with us for a period of time after his successor is appointed, to assist in the transition and to lead our global ERP initiative – the largest and most significant company-wide, internal initiative Haemonetics has embraced.”
Mr. Ryan will remain a member of the Company’s Operating Committee until his retirement.
Haemonetics (NYSE: HAE) is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collection, plasma collection, and blood component safety. To learn more about Haemonetics’ products and markets, visit its web site at http://www.haemonetics.com.
###